At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 176 enrolled
Drug / intervention
DRL-17822 or placebodrug
Likely dose
DRL-17822 or placebo 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients With Type II Hyperlipidemia
In Brief
A Phase 2 clinical trial evaluating DRL-17822 or placebo for Type II Hyperlipidemia. Completed, enrolled 176 participants across 12 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine if a new drug, DRL-17822, is safe and effective in elevating high density lipoprotein cholesterol (HDL-C) and reducing low density lipoprotein cholesterol (LDL-C) in people with abnormal cholesterol levels that may put them at risk for heart disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType II Hyperlipidemia
CountriesItaly, Poland, Ukraine
CollaboratorsPharmaNet
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedJul 2011
Primary CompletionMay 2012
Study CompletionJun 2012
TodayJul 2026
First PostedJul 7, 2011
Enrollment StartJul 1, 2011
Primary CompletionMay 1, 2012
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.0 years ago
Interventions
DRL-17822 or placebodrug
DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast